| pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
|---|
| advanced breast cancer (metastatic) | everolimus | not classified | versus CT everolimus + trastuzumab + vinorelbine superior to trastuzumab + vinorelbine alone in terms of PFS in BOLERO-3, 2014 | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| BOLERO-3, 2014 | everolimus + trastuzumab + vinorelbine vs trastuzumab + vinorelbine alone | PFS 0,78 [0,65; 0,94] Demonstrated | | |
| Trial | Treatments | Patients | Method |
|---|
| BOLERO-3, 2014 | daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m(2)) in 3-week cycles (n=284) vs. placebo plus trastuzumab plus vinorelbine, (n=285) | women with HER2-positive, trastuzumab-resistant, advanced breast carcinoma who had previously received taxane therapy | double-blind Parallel groups Sample size: 284/285 Primary endpoint: PFS by local assessment FU duration: |
|
| advanced breast cancer (metastatic) | everolimus | not classified | versus endocrine therapy alone everolimus + exemestane superior to exemestane alone in terms of PFS in BOLERO-2, 2011 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| BOLERO-2, 2011 | everolimus + exemestane vs exemestane alone | PFS 0,43 [0,35; 0,53] Demonstrated | | OS 0,89 [0,73; 1,09] | | TAMRAD , 2012 | everolimus + tamoxifen vs tamoxifen alone | OS 0,45 [0,24; 0,84] Time to progression (TTP) 0,54 [0,36; 0,81] | | |
| Trial | Treatments | Patients | Method |
|---|
| BOLERO-2, 2011 | everolimus and exemestane (n=485) vs. exemestane and placebo (n=239) | patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both). | double-blind Parallel groups Sample size: 485/239 Primary endpoint: progression-free survival FU duration: | | TAMRAD , 2012 | tamoxifen 20 mg/d plus everolimus 10 mg/d (n=54) vs. tamoxifen 20 mg/d alone (n=57) | postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, AI-resistant mBC | open-label Sample size: 54/57 Primary endpoint: FU duration: |
|
| advanced breast cancer (metastatic) | temsirolimus | not classified | versus endocrine therapy alone No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| HORIZON, 2013 | temsirolimus + letrozole vs letrozole alone | | | OS 0,89 [0,65; 1,22] PFS 0,90 [0,76; 1,07] |
| Trial | Treatments | Patients | Method |
|---|
| HORIZON, 2013 | oral letrozole 2.5 mg daily/temsirolimus 30 mg daily (5 days every 2 weeks) (n=556) vs. letrozole/placebo (n=556) | first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer | double-blind Parallel groups Sample size: 556/556 Primary endpoint: PFS FU duration: |
|
| renal-cell carcinoma (advanced) | everolimus | not classified | versus No demonstrated result for efficacy everolimus inferior to sunitinib in terms of PFS in RECORD 3, 2014 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| RECORD-1, 2008 | everolimus vs placebo | PFS 0,30 [0,22; 0,40] | | OS 0,83 [0,50; 1,37] | | RECORD 3, 2014 | everolimus vs sunitinib | | PFS 1,40 [1,14; 1,71] | |
| Trial | Treatments | Patients | Method |
|---|
| RECORD-1, 2008 | everolimus 10 mg once daily (n=272) vs. placebo (n=138) | Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both | Sample size: 272/138 Primary endpoint: PFS FU duration: | | RECORD 3, 2014 | everolimus (n=238) vs. sunitinib (n=233) | patients with metastatic renal cell carcinoma | Cross over Sample size: 238/233 Primary endpoint: FU duration: |
|
| renal-cell carcinoma (advanced) | temsirolimus | not classified | versus No demonstrated result for efficacy temsirolimus inferior to sorafenib in terms of OS in INTORSECT, 2014 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ARCC (Hudes) temsirolimus alone, 2007 | temsirolimus vs interferon alpha | OS 0,73 [0,58; 0,92] | | | | INTORSECT, 2014 | temsirolimus vs sorafenib | | OS 1,31 [1,05; 1,63] | PFS 0,87 [0,71; 1,07] |
| Trial | Treatments | Patients | Method |
|---|
| ARCC (Hudes) temsirolimus alone, 2007 | 25 mg of intravenoustemsirolimus weekly (n=209) vs. 3 million U of interferon alfa (with an increase to 18 millionU) subcutaneously three times weekly (n=207) 3 arms: Temsirolimus alone, Temsirolimus plus interferon and interferon alone | patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma | Sample size: 209/207 Primary endpoint: OS FU duration: | | INTORSECT, 2014 | temsirolimus 25 mg once weekly by intravenous (IV) infusion (n=259) vs. sorafenib 400 mg PO twice daily (n=253) | Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib | Sample size: 259/253 Primary endpoint: PFS FU duration: |
|
